Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
58,182,753
-
Share change
-
+5,035,338
-
Total reported value
-
$1,197,410,922
-
Put/Call ratio
-
42%
-
Price per share
-
$20.58
-
Number of holders
-
186
-
Value change
-
-$2,918,847
-
Number of buys
-
110
-
Number of sells
-
100
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q3 2023
As of 30 Sep 2023,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
186 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,182,753 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, RTW INVESTMENTS, LP, STATE STREET CORP, BlackRock Inc., Bellevue Group AG, JPMORGAN CHASE & CO, DIMENSIONAL FUND ADVISORS LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
189
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.